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Abstract (123<150 words) 1 
Amyloid β-protein (Aβ) oligomers, intermediates of Aβ aggregation, cause cognitive 2 
impairment and synaptotoxicity in the pathogenesis of Alzheimer’s disease (AD).  3 
Immunotherapy using anti-Aβ antibody is one of the most promising approaches for AD 4 
treatment.  However, most clinical trials using conventional sequence-specific antibodies 5 
have proceeded with difficulty.  This is probably due to the unintended removal of the 6 
non-pathological monomer and fibrils of Aβ as well as the pathological oligomers by these 7 
antibodies that recognize Aβ sequence, which is not involved in synaptotoxicity.  Several 8 
efforts have been made recently to develop conformation-specific antibodies that target the 9 
tertiary structure of Aβ oligomers.  Here we review the recent findings of Aβ oligomers and 10 
anti-Aβ antibodies including our own, and discuss their potential as therapeutic and 11 
diagnostic tools. 12 
 13 
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Accumulation of aggregated proteins is characteristic of many neurodegenerative diseases 2 
including Alzheimer’s disease (AD), Parkinson’s disease, and Huntington’s disease.  AD is 3 
generally characterized by the aggregation of extracellular amyloid β-protein (Aβ) in senile 4 
plaques.  Aβ mainly consists of 40- and 42-mer amyloid β peptides (Aβ40, Aβ42), which are 5 
predominantly secreted from Aβ protein precursor (APP) by two proteases (β- and 6 
 γ-secretases).1,2)  β-Secretase is identified as an aspartyl protease of the pepsin family, called 7 
β-site APP-cleaving enzyme (BACE-1).3)  It is noted in amyloid theory that Aβ aggregates 8 
through β-sheet formation and shows neurotoxicity.  On the other hand, neurofibrillary 9 
tangles (NFTs) are another feature of AD pathology and are composed of intracellular 10 
deposits of tau protein.4,5)  Abnormal aggregation of tau is related to its hyperphosphorylation.  11 
Recent clinical reports by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) support 12 
the amyloid theory; the accumulation of Aβ occurs earliest during the process of AD as a 13 
molecular trigger, followed by neuronal injury, deposition of phosphorylated tau, and a 14 
shrunken hippocampus, respectively.6)  The pre-symptomatic and mild cognitive impairment 15 
(MCI) stages, prior to AD onset, are dependent on progression based on these biomarkers (Fig. 16 
1). 17 
The cleavage of APP by BACE-1 generates a secreted APPβ (sAPPβ) and a 18 
membrane-bound C-terminal fragment of APP (CTFβ), which is a precursor of the following 19 
cleavage by γ-secretase (amyloidogenic pathway, Fig. 2).  Two homologous presenilins, 20 
presenilin 1 (PS1) and presenilin 2 (PS2), play an important role in γ-secretase activity, which 21 
requires three other cofactors: nicastrin (Nct), anterior pharynx-defective phenotype (APH-1), 22 
and presenilin-enhancer (PEN-2).7)  The broad substrate specificity of γ-secretase at the 23 
C-terminal region of APP results in the multiple production of other lengths of Aβs (e.g. 37-, 24 
38- or 43-mer).8,9)  Additional Aβ heterogeneity is generated by an enzymatic reaction: 25 
isomerase (Asp7, Asp23),10,11) glutaminylcyclase (Glu3, Glu11),11,12) aminopeptidases 26 
(Aβ3-42),11) and phosphorylation (Ser8).13)  Despite recent rediscovery of the potent 27 
amyloidogenicity and pathogenicity of Aβ4314) in the animal study, the aggregative ability and 28 
 4 
neurotoxicity of Aβ43 does not exceed those of Aβ42.15)  These findings suggest that Aβ42 or 1 
these modification products of Aβ42 plays the most critical role in the pathogenesis of AD.16)   2 
On the other hand, APP is cleaved by α-secretase between residues 16 and 17 to produce 3 
secreted APPα (sAPPα) and the C-terminal fragment (CTFα), resulting in no production of 4 
Aβ40 and Aβ42 from these cleaved precursors (non-amyloidogenic pathway, Fig. 2).  5 
Concurrently, smaller fragments, referred to as p3 (Aβ17-40/42) and APP intracellular domain 6 
(AICD), are produced.  The physiological role of these APP metabolites remains unclear in 7 
spite of their ubiquitous expression in almost all human organs.  Furthermore, a proportion of 8 
Aβ is also modulated by degrading enzymes, such as insulin-degrading enzyme17) and 9 
neprilysin.18) 10 
Although most of the present clinical drugs in AD target glutamatergic and cholinergic 11 
neurotransmission, their benefits are limited in terms of symptomatic treatments.  12 
Disease-modifying drugs to prevent the aggregation of Aβ, to hinder the production of Aβ, 13 
and to enhance the degrading activity of Aβ are currently being developed.  In particular, 14 
immunotherapy using anti-Aβ antibody for Aβ clearance and anti-aggregation has been 15 
intensively examined in clinical trials.19)  However, some conventional antibodies targeting 16 
Aβ sequence are struggling in trials.  In recent years, conformation§-specific antibodies that 17 
target synaptotoxic Aβ oligomers (intermediate aggregates), rather than the physiological Aβ 18 
monomer and fibrils, have received a lot of attention.  In the following chapters, this review 19 
focuses on the features of Aβ oligomers and unique attempts to develop antibodies against Aβ 20 
oligomers, and introduces our findings of a monoclonal antibody against a toxic conformer§§ 21 
of Aβ42 together with its application to AD treatment. 22 
 23 
I. Amyloid β  Oligomer Hypothesis 24 
1. Aβ oligomers 25 
There is increasing evidence that soluble oligomeric assemblies of Aβ can induce 26 
cognitive decline and synaptic dysfunction in the pathology of AD,20) whereas mature plaques 27 
composed of insoluble fibrils are not always consistent with neuronal degeneration21,22) and 28 
 5 
serve as a store of the toxic assembly of Aβ.23)  Accumulated studies on the etiology of Aβ 1 
assemblies; paranucleus (5-mer),24) Aβ*56 (56 kDa, 12-mer),25) protofibrils (24~700-mer),26,27) 2 
globulomer (38/48 kDa, ~12-mer),28) AβO (~90 kDa, 15~20-mer),29) Aβ-derived diffusible 3 
ligands (ADDLs; ~90 kDa, ~24-mer),30) annulus (150~250 kDa, ~50-mer),31) and 4 
amylospheroid (ASPD; 158~669 kDa, ~100-mer)32) have been appreciated (Fig. 3, Table 1).  5 
Paranucleus is supposed to be a unit of protofibrils.  In particular, the synaptotoxic potentials 6 
of ADDLs are well studied, and they are extensively used as an oligomer model.  These 7 
synaptotoxic high molecular-weight oligomers are composed of a dimer and/or trimer as a 8 
minimum unit of Aβ assemblies (2 x n-mer, 3 x n-mer).33,34)  More correctly, Aβ40 preferably 9 
exists as dimer,35) while Aβ42 likely form trimer or tetramer.36)  Studies using synthetic dimers 10 
(S26C-Aβ40)37) and in vivo-derived dimers37) and trimers38) support their significance to the 11 
synaptotoxicity.   12 
 13 
2. Synaptotoxicity 14 
Long-term potentiation (LTP) is a lasting enhancement in signal transmission among 15 
neurons, reflecting synaptic health.39)  Synthetic Aβ oligomers (ADDLs),30) brain-derived 16 
oligomers (Aβ*56)25) from AD transgenic mice (Tg2576 line), and dimers37) from human AD 17 
patients inhibit LTP and induce dendritic spine shrinkage in rat neurons, resulting in 18 
synaptotoxicity in the CA1 region of the hippocampus.  Because memory loss is closely 19 
related to synaptotoxicity, the removal of Aβ oligomers and prevention of oligomer formation 20 
would be a promising approach for AD therapeutics.  Shankar et al. demonstrated that the 21 
inhibition of LTP was neutralized by the administration of anti-Aβ antibodies to a rat model 22 
of AD.37)   23 
 24 
3. Oxidative stress 25 
Oxidative stress induced from reactive oxygen species (ROS; e.g. superoxide radical, 26 
hydroxyl radical) is an early event underlying synaptotoxicity and the subsequent neuronal 27 
death by Aβ oligomer.  Reports using human brain materials show a strong correlation 28 
 6 
between oxidative damage levels (total SOD, catalase, glutathione, protein carbonyls, 1 
thiobarbituric acid reactive substances, 3-nitrotyrosine, 4-hydroxynonenal, and acrolein) and 2 
the dementia status of subjects.40)  Klein and colleagues proposed that ADDLs induce LTP 3 
accompanied with oxidative damage ex vivo.41)  Barnham and colleagues proposed that Aβ 4 
forms dityrosine cross-linked dimers via oxidation of the tyrosine residue at position 10 5 
(Tyr10) under oxidative conditions,42) and that generic dityrosine levels were also elevated in 6 
the AD brain.43)   7 
Superoxide dismutase (SOD) is one of the major antioxidant metallo-enzymes converting 8 
toxic superoxide radicals to hydrogen peroxide.  In AD brains, the amount of CuZn-SOD 9 
(SOD1), which is found in the peroxisomes and nucleus as well as in the cytosol and 10 
intermembrane space of mitochondria, was larger than in non-AD cases.44)  On the other hand, 11 
no such increase was found in Mn-SOD (SOD2) in the mitochondrial matrix or in 12 
extracellular CuZn-SOD (SOD3) in specific cell types, such as vascular smooth muscular 13 
cells, lungs, and plasma.44)  Furthermore, to evaluate the contribution of SOD1 to AD 14 
progression, our group previously bred Sod1-deficient mice (Sod1–/–), which showed drusen 15 
deposition,45) fatty liver,46) skin thinning,47) and osteoporosis,48) as a senescence model, with an 16 
APP transgenic mouse model (Tg2576) as an AD model.  In the resultant double transgenic 17 
mice (hAPP/Sod1–/–), Aβ oligomerization associated with memory loss and synaptic loss 18 
worsened as compared with control AD mice.44)  BACE1 amounts were also augmented in 19 
hAPP/Sod1–/–, implying stimulation of the amyloidogenic pathway by cytoplasmic superoxide 20 
radicals.49)  The relevance of oxidative stress to oligomer formation of Aβ in the etiology of 21 
AD was described in the previous review.50) 22 
 23 
4. Target receptors  24 
It is still unclear how Aβ oligomer interferes with signaling pathways to inhibit LTP 25 
activity.  Some candidates for oligomer-targeted receptors at the synaptic plasma membrane 26 
have been reported.  Snyder et al. suggested that the application of naturally secreted Aβ 27 
oligomers to cortical slices promoted the endocytosis of N-methyl-D-aspartate (NMDA) 28 
 7 
receptors by binding the oligomers to  α7-nicotinic receptors.51)  Subsequently, the 1 
disturbance of NMDA function affected calcium influx and the downstream cascades, such as 2 
AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole) receptors.52)  Aβ oligomers also interacted 3 
with RAGE (receptor for advanced glycation endproducts) receptor53) and the insulin 4 
receptor54) to induce oxidative stress.  Notably, the cellular prion protein (PrPC) functions as a 5 
specific receptor for Aβ oligomers to inhibit LTP activity and to disrupt insulin activity.55)  6 
These interactions could be dependent on the size, polarity, and conformations of Aβ 7 
oligomers.   8 
 9 
II. Aβ  Immunotherapy 10 
1. Active immunization 11 
Solomon et al. reported that anti-Aβ antibody prevented the aggregation of Aβ56) and 12 
disaggregated the pre-existed fibril of Aβ using thioflavin T,57) which is a reagent showing 13 
fluorescence by binding the β-sheet structure within amyloid aggregates.58)  In 1999, Schenk 14 
et al. first demonstrated active immunization using an AD mouse model (PDAPP).  In this 15 
study, the administration of synthetic Aβ42 to animals led to a reduction of plaque area59), and 16 
recovery of cognitive impairment was also reported in later studies.60,61)  Subsequently, an 17 
experiment using 3xTg-AD mice showed that behavioral improvement by immunization was 18 
related to the reduction of Aβ oligomer levels,62) indicating Aβ oligomers as more optimal 19 
targets than plaques for AD treatment. 20 
In a clinical trial (AN1792) in which Elan and Wyeth initiated active immunization in 21 
2001, synthetic Aβ42 combined with the surface-active saponin adjuvant QS-21 was 22 
vaccinated.  Although phase I was safely conducted, phase II was halted because of severe 23 
adverse effects (aseptic meningoencephalitis) in ~6% of patients.63)  The subsequent follow-up 24 
study indicated that Aβ plaques were reduced in AD patients but not progressive cognitive 25 
impairment.64)  This was likely due to the unintended removal of both pathological and 26 
non-pathological Aβ42; the role of the latter in physiological function is currently 27 
controversial.  Soscia et al. reported one interesting study on the involvement of Aβ42 in the 28 
 8 
immune system as an antimicrobial protein.65)  Alternatively, the involvement of the excessive 1 
induction of T-helper (TH) 1 lymphocytes by QS-21 adjuvant has been noted, which causes 2 
the strong response of the cell-mediated immune system in order to enhance antibody 3 
responses in the elderly.   4 
 5 
2. Passive immunization 6 
Active Aβ immunization is cost-effective and long-lasting with only a few injections, 7 
although it is difficult to avoid the risk of undesirable immune responses because of the use of 8 
strong adjuvants to boost antibody generation.  In contrast, passive immunization by the 9 
intravenous administration of antibodies is moderate even in the elderly, whose 10 
proinflammatory cytokine levels are normally higher,66) and it can be halted at any time if 11 
adverse events occur.  Additionally, the usage of antibodies only directing the target agent of 12 
interest, such as toxic Aβ assemblies or conformations, is one of their advantages over active 13 
immunization.   14 
So far, over 600 antibodies against Aβ have been deposited in Alzforum 15 
(http://www.alzforum.org/), and most of these were dependent on the Aβ sequence.  The 16 
initial application of passive immunotherapy using AD mice (PDAPP) described that 17 
treatment with anti-Aβ N-terminus monoclonal (3D6) antibodies prevented plaque formation, 18 
but not anti-Aβ C-terminus monoclonal antibodies.67)  In particular, the binding of antibody to 19 
amyloid plaque could induce the microglical phagocytosis of Aβ burden through Fc 20 
receptor.67)  Also, the injection of anti-Aβ middle portion antibody (m266), whose epitope lies 21 
in Aβ13-28, to young PDAPP mice prevented plaque formation and decreased the levels of 22 
soluble Aβ.68)  The complex of Aβ with antibody in the blood was detected in this study, 23 
supporting the potent role of anti-Aβ antibody therapy in AD prevention.  These therapeutic 24 
effects are suggested to be mediated by the following inhibitory mechanisms: (1) the complex 25 
formation of Aβ with antibodies could induce binding of the Fc portion to microglia, leading 26 
to the phagocytosis of these complexes.67)  (2) The antibodies could directly prevent the 27 
aggregation (oligomerization) of Aβ.69)  These mechanisms are based on the assumption that 28 
 9 
antibodies can cross the blood–brain barrier (BBB) in order to bind Aβ within the brain.  1 
There is an alternative idea that antibodies in the blood might induce a shift in the 2 
concentration gradient of Aβ over BBB, followed by increased efflux of Aβ from the brain to 3 
the periphery (sink hypothesis).68) 4 
However, some animal experiments using other sequence-specific antibodies of Aβ led to 5 
the occurrence of microhemorrhages in the regions of cerebral amyloid angiopathy, despite 6 
the mitigation of senile plaques and neuritic dystrophy.70,71)  Recently, the humanized antibody 7 
(bapineuzumab) of 3D6 was tested in clinical trials.  Although bapinezumab reduced Aβ 8 
plaques examined by plaque-detective positron emission tomography (PET) imaging in AD 9 
patients in phase III, almost no clinical benefits were observed, thus resulting in the 10 
termination of this trial, according to the report by Lemere et al.72)  These problems may have 11 
occurred because the treatment was too late to recover from neurodegenerative decline during 12 
the disease process.73,74)  It is therefore indispensable to develop highly sensitive 13 
oligomer-specific antibodies for the purpose of early diagnosis and passive immunization in 14 
AD therapeutics. 15 
 16 
III. Conformation-specific Antibodies to Target Aβ  Oligomers 17 
Wirth et al. reported no association of Aβ plaques by [11C] Pittsburgh compound B (PiB) 18 
PET and neuronal degeneration in older subjects with normal cognition.75)  These findings 19 
imply the need for a novel detection tool for oligomeric Aβ in place of PiB, which is one of 20 
the most reliable techniques for amyloid detection in clinical practice.  If the involvement of 21 
tau hyperphosphorylation and accumulation is considered in AD pathology, these may be 22 
stimulated by Aβ oligomers.76)  However, well-established detection reagents of Aβ oligomers 23 
are presently lacking.  Considering the difference of conformations between Aβ oligomers 24 
and fibrils based on previous NMR analysis,77) several endeavors have been made to develop 25 
conformation-specific antibodies to target Aβ oligomers (Table 1). 26 
 27 
1. A11, OC,  αAPF antibody 28 
 10 
Glabe and colleagues generated an oligomer-specific antibody (A11), which does not 1 
recognize Aβ fibrils and also reacts with other types of amyloid oligomers (α-synuclein in 2 
Parkinson’s disease, polyglutamine in Huntington’s disease, and prion peptide 106-126 in 3 
prion disease), using a molecular mimic of the presumed organization of Aβ oligomers.78)  4 
They used Aβ40 octamer as a hapten, which was synthesized by conjugating the C-terminal 5 
thioester Aβ40 to colloidal gold nanoparticles.  The gold-coupled Aβ40 octamer forms a 6 
typical β-sheet structure in the circular dichroism (CD) spectra.79)  This octamer is also 7 
spherical in atomic force microscopy, but weak in thioflavin T fluorescence.79)  This is the 8 
first antibody that binds intermediates of Aβ aggregation, but not fibrillar Aβ.80)  In fact, 9 
immunohistochemistry using human AD brains showed that the localization of A11 staining 10 
was different from that of thioflavin staining.78) 11 
Subsequently, they produced OC antibody by immunizing with Aβ42 fibrils, and OC 12 
recognized only amyloid fibrils, not prefibrillar oligomer detected by A11.81)  The mechanism 13 
of A11-positive prefibrillar oligomer formation is proposed to be distinct from that of 14 
OC-positive fibrillar oligomer formation.  They also identified the annular protofibrillar 15 
oligomer (αAPF), and made an antiserum selective for αAPF as the second generation of 16 
A11.82) 17 
Regarding the application of these antibodies to the diagnosis, they performed dot blotting 18 
using human materials.  The levels of soluble fibrillar oligomer detected by OC were larger in 19 
AD brain extracts than in age-matched individuals, and these increased levels were associated 20 
with cognitive decline.  Surprisingly, levels of soluble prefibrillar oligomer by A11 and αAPF 21 
were not associated.83)  Similar results were obtained in the experiment using mouse brain 22 
extracts.84)  These results raise another concern that there are at least two classes of oligomers: 23 
oligomers supposed to move into the fibrillar stage (on-pathway) or those supposed to remain 24 
as the intermediate (off-pathway) (Fig. 3).  These also suggest that fibrillar deposition may 25 
not be necessarily as benign as previously considered.  Recent research also showed that 26 
αAPF levels in the cerebrospinal fluid (CSF) were elevated during the presymptomatic phase 27 
in a hereditary (familial) AD patient.85)  αAPF might be an optimized biomarker for the early 28 
 11 
diagnosis of AD.  1 
 2 
2. Anti-ADDLs antibody 3 
Klein and colleagues found that Aβ42-derived ADDLs blocked LTP by binding to 4 
synaptic terminals.30)  Aβ40 failed to form ADDLs.  Anti-ADDLs antibody (NU-1) was 5 
developed based on its ability to discriminate an AD brain from a control brain.86)  Although 6 
these antibodies were generated by immunization with ADDLs, the epitope of NU-1 likely lay 7 
in the Aβ sequence (Aβ1-28) or its assemblies.  Neutralization by these antibodies 8 
significantly rescued Aβ42-induced LTP inhibition as well as ROS.86)  The amounts of 9 
ADDLs were enhanced in CSF and brain extracts of AD.87,88) 10 
Shughrue et al. also produced an antibody against ADDLs according to the method 11 
developed by Klein and colleagues, and one clone (ACU-954) significantly inhibited the loss 12 
of dendritic spines induced by ADDLs through its binding to hippocampal neurons.89)  13 
ACU-954 also detected naturally-occurring ADDLs in AD brains, which was localized in the 14 
hippocampal dendritic spines as well as in the cortex, but not within neuronal cells.89) 15 
 16 
3. Anti-ASPD antibody 17 
Hoshi and colleagues generated monoclonal antibodies (rpASD1, mASD3) against 18 
amylospheroid (ASPD), which are considered to be an off-pathway product of Aβ 19 
intermediates because ASPD were not included in mature fibrils and were different from 20 
ADDLs in morphology and size.90)  They isolated 10~15-nm spherical Aβ oligomer (named as 21 
native ASPD) by immunoisolation using anti-ASPD antibodies from AD brains.  The amount 22 
of native ASPD correlated with the severity of AD.  These antibodies also immunostained 23 
dense-core plaques in cryosections as well as paraffin sections of AD brains.  Based on an 24 
experiment using the antibodies, they proposed that ASPD-mediated toxicity has a distinct 25 
mechanism from other oligomers, where ASPD binds a presynaptic target in an 26 
NMDA-receptor-independent manner.90) 27 
The subsequent study by the same group using a combination measurement of 28 
 12 
fluorescence correlation spectroscopy and transmission electron microscopy showed that the 1 
formation of ASPD begins with a trimer, whereas the initial step of fibrillogenesis is 2 
dimerization.91)  The oligomeric size of most toxic ASPD was ~32-mer (~128 kDa).  These 3 
findings raise a future concern how dimers and trimers show such different toxicity profiles. 4 
 5 
4. Anti-globulomer antibody 6 
Hillen and colleagues developed an antibody (A-887755) against synthetic oligomer 7 
(globulomer), whose conformation is different from that of Aβ monomer or fibril.92)  In this 8 
study, Aβ20-42 was used for preparation of globulomer.  They originally found a globulomer 9 
made from Aβ42, which is supposed to be a stable neurotoxin,28) and showed that Aβ42 10 
globulomer inhibited spontaneous synaptic function by modulation of the P/Q-type calcium 11 
current.93)  They used a truncated peptide (Aβ20-42) to avoid the reactivity of all Aβ species 12 
(monomers, oligomers, fibrils) because of the broad immunogenicity of N-terminal regions.  13 
Indeed, the antibody (6G1) against Aβ42 globulomer did not discriminate among monomers, 14 
oligomers, and fibrils.28) 15 
In immnoprecipitation experiments, A-887755 did not recognize Aβ monomer in the CSF 16 
and plasma of AD patients.  More importantly, A-887755 did not immunolable senile plaque 17 
in AD brains (e.g. brain parenchym and vessel),92) suggesting little cross-reactivity of 18 
oligomer-targeted A-887755 antibody with Aβ monomer and deposits.  Aβ20-42 19 
globulomer-induced synaptotoxicity was also neutralized by A-887755.  Regarding the 20 
therapeutic approach, active immunization with Aβ20-42 globulomer improved the impaired 21 
novel object recognition.  Furthermore, passive immunization with A-887755 rescued 22 
cognitive impairment as well as synaptic spine density in AD mice.92)  Considering adverse 23 
effects with the removal of plaques, A-887755 might be a good candidate for an AD 24 
therapeutic agent. 25 
 26 
5. Grafted amyloid-motif antibody (Gammabody) 27 
Tessier and colleagues proposed a unique “grafting” approach to develop conformation- 28 
 13 
and sequence-specific antibodies for Aβ.94)  This approach is based on the concept, originated 1 
by Williamson and colleagues,95) that selectivity against aggregated Aβ conformers can be 2 
enhanced by grafting the Aβ sequence responsible for aggregation into the 3 
complementarity-determining region (CDR) in the FV domain of antibodies, which are 4 
generally bound to antigens.  They focused on the third CDR (CDR3) of an antibody domain 5 
(VH), whose structure has been identified (PDB: 3B9V).  The folding of VH, which is a stable 6 
scaffold, is insensitive to point mutations in the CDR3 loop motif.96)  Systematic grafting of 7 
the Aβ sequence revealed that the antibody including the central region (Val18-Ala21) bound 8 
to Aβ fibrils, and the antibody including the C-terminal region (Leu34-Ala21) reacted with 9 
Aβ oligomers as well as fibrils.  However, an oligomer-specific antibody was not obtained.  10 
Such broad reactivity may be why the selected grafting sequence is shared between the 11 
formation of oligomers and fibrils.  Immunohistochemistry has not been performed.   12 
In subsequent studies, these antibodies inhibited the aggregation of Aβ42 by forming 13 
Aβ-antibody complex, which was detected by size-exclusion chromatography.97)  These 14 
approaches were expanded to other amyloid proteins: islet amyloid polypeptide (type 2 15 
diabetes) and α-synuclein (Parkinson’s disease).   16 
 17 
6. Antibodies generated by phage display 18 
Phage display is a conventional and powerful technique for antibody selection from 19 
libraries by inserting a gene encoding a protein of interest into a phage gene.  In general, a 20 
virus with the ability to infect and replicate within bacteria is used as a bacteriophage.  21 
Fändrich and colleagues demonstrated a phage display using a recombinant library of the 22 
camelid VHH domain, and selected the conformation-sensitive VHH-domain B10 by repeated 23 
panning using Aβ40 fibrils.98)  The B10 antibody recognized only mature fibrils and prevented 24 
fibrillization by stabilizing Aβ40 protofibril.   25 
Their next target was Aβ40 oligomer.  The reactivity of the obtained antibody (KW1) in a 26 
similar approach was dependent on a hydrophobic and aromatic motif including Aβ fragment 27 
(Aβ18-20), which was in good agreement with the results from NMR analysis of the 28 
 14 
interaction of Aβ40 with KW1.99)  KW1 bound to high molecular-weight oligomers rather 1 
than fibrils and detected brain-derived oligomers in AD patients.   2 
Cattaneo and colleagues carried out advanced phage display selection using an anti-Aβ 3 
single chain FV domain by targeting intracellular Aβ oligomers.100)  They expressed a 4 
LexA-Aβ42 fusion protein in yeast cells, and several antibodies were obtained against these 5 
intracellular antigens.  The antibodies immunostained senile deposits in the AD brain, and the 6 
intracellular deposits were also confirmed in the cell-based experiment.  These antibodies also 7 
inhibited ADDLs-induced toxicity in cell cultures by preventing the binding of ADDLs to the 8 
synapse.  This will help us to understand the processing and trafficking of intracellular Aβ 9 
oligomers. 10 
 11 
IV. Antibodies against toxic conformer of Aβ42 12 
Despite accumulated structural research using NMR, MS, and X-ray crystallography on 13 
Aβ42101) and Aβ40,102,103) studies focusing on the relationship between conformer and 14 
neurotoxicity are limited.  We have previously proposed the toxic conformer of Aβ42 with a 15 
turn at positions 22 and 23, and that this conformer could preferably form oligomeric 16 
conformation.  Our strategy is to develop the oligomer-targeted antibodies based on the 17 
theory of the toxic conformer of Aβ42.104)   18 
 19 
1. Toxic conformer of Aβ42 20 
Some investigations clarified that the S-oxidized radical cation in Met35 of Aβ42 is 21 
closely related to its neurotoxicity.  However, it remains fully unanswered how the radical is 22 
formed to induce toxic effects.  Moreover, Met35 radical is generally too unstable to cause 23 
oxidative damage continuously.105)  Our continued research, including systematic proline 24 
replacement and electron spin resonance (ESR), demonstrated that the turn structure at 25 
positions 22 and 23 could bring a phenoxy radical into Tyr10, which was generated through 26 
trace metals, close to Met35, resulting in the generation of the S-oxidized radical cation in 27 
Met35 (Fig. 4A).  Another turn at Gly38 and Val39 as well as the turn at Glu22 and Asp23 28 
 15 
was also involved in aggregation and neurotoxicity.106)  Such an additional C-terminal turn 1 
could play a role in the stabilization of the S-oxidized radical cation by forming an S-O 2 
bonding with a carboxylate anion at Ala42 at the C-terminal core (Fig. 4A).  Collectively, the 3 
resultant core facilitated by an intramolecular β-sheet (Met35~Ala42) would contribute to 4 
long-lasting oxidative stress, that is, the neurotoxicity,15) and thus we have proposed the toxic 5 
conformer of Aβ42 with a turn at positions 22 and 23.  Further research using solid-state 6 
NMR clarified the existence of a non-toxic conformer with a turn at positions 25 and 26 in 7 
Aβ42 aggregates as well as a toxic conformer with a turn at positions 22 and 23107-109) (Fig. 8 
4B).  In the following study by Masuda et al., the Aβ42-lactam (E22K-D23E), in which the 9 
side chains of Lys22 and Glu23 in the toxic conformer are linked with an amide bond, 10 
enhanced oligomer (mainly trimer) formation and the radical-generating ability of Aβ42 as 11 
well as the aggregative ability (oligomerization) and neurotoxicity.  In contrast, the 12 
Aβ42-lactam (G25K-S26E), in which the side chains of Lys25 and Glu26 in the non-toxic 13 
conformer are similarly linked, did not.108)  Aβ42 mutant (E22P-Aβ42) with a high ability to 14 
form the toxic conformer induced the synaptotoxicity on the rat hippocampal slices.110)  These 15 
findins strongly suggest that the formation of toxic conformer could be required to facilitate 16 
the oligomeric conformation (termed as “toxic oligomer”). 17 
 18 
2. 11A1 antibody 19 
We next tried to develop a monoclonal antibody against the toxic conformer of Aβ42.  The 20 
truncated Aβ peptide (E22P-Aβ10-35) including a toxic turn at positions 22 and 23, as a 21 
Pro-X corner (X: variable amino acid residue),111) based on the optimum length (Aβ10-35) for 22 
neurotoxicity,15) was utilized as a hapten (Fig. 4B).  To address whether the obtained antibody 23 
(termed 11A1)104) can react with Aβ oligomers or not, a brain soluble fraction was prepared 24 
for western blotting.  11A1 bound a low-molecular-weight oligomer (predominantly trimer), 25 
whereas 4G8 against Aβ17-24 and 82E1112) against the N-terminus of Aβ, recognized mainly 26 
the monomer.  These observation are consistent with the previous data that Aβ42 mutants 27 
with a potent propensity to form a turn structure at positions 22 and 23 accelerated Aβ 28 
 16 
oligomerization.108)   1 
MTT assay is one of the evaluation methods for Aβ-mediated neurotoxicity.  The 2 
neurotoxicity of Aβ42 on PC12 cells was recovered by 11A1, but not by 4G8.104)  11A1 also 3 
inhibited the cytotoxicity of E22P-Aβ42, which can more readily form the toxic conformer of 4 
Aβ42.  Similar results were obtained in the test using rat primary neurons.113)  The following 5 
dot blotting study of Aβ42 demonstrated the gradual increase of 11A1 reactivity in a 6 
time-dependent manner, which preceded neurotoxicity.114)  On the other hand, the 7 
immunoreactivity of Aβ42 by other sequence-specific antibodies remained constant.  8 
Moreover, 11A1 potently detected the toxic conformer in Aβ42 mutants related to familial Aβ 9 
mutations, such as Italian (E22K) and Arctic (E22G),114) which augmented neurotoxicity as 10 
well as the aggregative ability of Aβ42.115)  The neurotoxic effects of these mutants were in 11 
good agreement with the levels of reactive oxidative stress tested by the 12 
2’,7’-dichlorodihydrofluorescein (DCF) assay,114) supporting the critical role of 13 
oligomerization induced from toxic Aβ42 conformers in oxidative stress.   14 
 15 
3. Intracellular Aβ 16 
Although the accumulation of oligomeric Aβ within neuronal cells has been considered to 17 
be one of the early events during AD progression, there is little information on the 18 
conformation of intraneuronal Aβ aggregates.116)  It has been reported that the intracellular Aβ 19 
oligomer accumulates in the endoplasmic reticulum (ER), endosomes, lysosomes, and 20 
mitochondria.117)  Intracellular Aβ deposition precedes the accumulation of extracellular 21 
Aβ.118)  Mitochondrial toxicity, proteasome impairment, and synaptic damage due to 22 
intracellular Aβ have been identified.119)  Our immunohistochemical studies using the frontal 23 
lobe and hippocampus of AD patients (provided by Dr. Shigeo Murayama of the Brain Bank 24 
for Aging Research, Tokyo Metropolitan Institute of Gerontology) showed that 11A1 25 
recognized not only typical amyloid plaques but also potent intracellular staining (Fig. 4B).  26 
On the other hand, only extracellular amyloid plaques were stained by other 27 
sequence-dependent antibodies.104)  Interestingly, mild intracellular staining of 11A1 was 28 
 17 
found even in non-AD individuals, suggesting that 11A1 can detect toxic species of Aβ within 1 
cells before the onset of AD.  These do not contradict the previous results118) of the potent 2 
immunoreactivity of intracellular Aβ in a patient with MCI. 3 
Similar results using 11A1 have been followed by other researchers.  Ohyagi and 4 
colleagues showed that intraneuronal staining by 11A1 was more closely related to the onset 5 
of memory impairment in 3xTg-AD mice than that by 4G8.120)  They also found the 6 
co-localization of 11A1-positive deposits with GRP78, an ER stress marker, in AD brain 7 
sections, whose expression was associated with cognitive impairment and dysfunction of 8 
endsomes and Golgi-ER trafficking.120)  Kulic et al. developed APP transgenic mice with 9 
double mutations of Swedish (K670N/M671L in APP) and Osaka (E693Δ in APP), and 10 
observed the early depositions of intracellular fibrillar oligomers (11A1-positive) coupled 11 
with early memory decline.121)  Osaka mutation (E22Δ in Aβ) favoring oligomerization 12 
induced the potent synaptotoxicity of Aβ42,122) but not Aβ40.110)  Inoue and colleagues using 13 
11A1 demonstrated intracellular accumulation of Aβ oligomers with toxic conformer in 14 
neuronal cells derived from induced pluripotent stem cells (iPSCs), which were obtained from 15 
sporadic patients and a familial AD patient with Osaka mutation.123)  Interestingly, 16 
anti-ADDLs antibody (NU-1) also immunostained intracellular Aβ similarly to 11A1.  11A1 17 
is thus a unique antibody that preferably recognizes intracellular amyloid in the human brain 18 
along with senile plaques.  These findings highlight that the toxic conformer of Aβ42 could 19 
accumulate within neurons at the early stage during AD progression.   20 
Regarding the intracellular accumulation of Aβ in AD pathology, key questions of how 21 
intracellular Aβ accumulates remain unanswered, that is, whether Aβ is partially secreted into 22 
the extracellular space but remains intracellular, or whether secreted Aβ is transported into the 23 
intracellular space.  Indeed, some transporters involved in the internalization of Aβ have been 24 
reported; the scavenger receptor for advanced glycation end products (RAGE)53) and the 25 
formyl peptide receptor-like 1 (FPRL1).53,124)  Notably, extracellular plaques increase, while 26 
intracellular depositions of Aβ decrease.125)  Considering the involvement of tau pathology, 27 
intraneuronal Aβ co-existed with NFT inside the neurons.4,126)  Intracellular Aβ may trigger 28 
 18 
tau hyperphosphorylation and mitochondrial dysfunction to induce synaptotoxicity.  Because 1 
the deposition of tau protein starts about 10 years later than Aβ accumulation (Fig. 1), a 2 
mediator regulating the cross-talk of Aβ with tau may exist.  Quite recently, the synergistical 3 
interaction between the accumulation of 11A1-positive intracellular Aβ and human tau could 4 
accelerate each other’s aggregation.127)  These indicate the meditation role of toxic conformer 5 
of Aβ42 in AD pathology. 6 
 7 
V. Conclusions and Future Directions 8 
Given the growing medical and social burden, the necessity of the early resolution of AD 9 
is stronger than ever.  To date, anti-Aβ drugs have been developed;128) these are mainly 10 
divided into three strategies: (1) anti-aggregation and clearance, (2) secretase inhibitors, (3) 11 
Aβ degradation activator.  Since symptomatic drugs (denopezil, memantine, rivastigmine, and 12 
galantamine) have been established, these combination strategies based on an early diagnosis 13 
will be more effective.  Several structure-based designs of aggregation inhibitors have been 14 
also recently reported.129-131)  Conformation-specific antibodies to target the characteristic 15 
structure of Aβ oligomers will shed new light on the accurate diagnosis by ELISA 16 
development and vaccination therapy.  Eventually, it may be possible to extend the diagnosis 17 
and intervention to asymptomatic people. 18 
In the application of antibodies to ELISA development, the approach of two-site ELISA 19 
has received attention, in which the same sequence-specific antibody (82E1132) or Ban50133) 20 
against Aβ1-16) for capture and detection is used.  These approaches revealed a clear 21 
correlation of the oligomer levels in the plasma and brain extracts132) and CSF133) in various 22 
cognitive levels of AD patients.  A recent study using brain lysates showed that two-site 23 
ELISA of the antibody (HJ3.4) against the N-terminal Aβ discriminated Aβ dimer from 24 
monomer, but the result that HJ3.4 did not discriminate oligomers from plaques caused 25 
confusion.134)  Such a strategy aiming at ELISA specificity is questioned.  Because 2 x n-mer 26 
oligomers with high molecular weight as well as the dimer can be theoretically detected in 27 
these strategies, oligomer levels in healthy individuals may be overestimated.135)  Two-site 28 
 19 
ELISA recently generated by the same group to target ADDLs using a modified ACU-954 1 
conjugated with a bead-based fluorescent platform was improved in this aspect.136)  2 
Prospectively, the application of conformation-specific antibodies such as 11A1 into ELISA 3 
is promising. 4 
Indeed, only a few antibodies can cross the BBB (0.1–0.2%).137)  Even if unprecedented 5 
antibodies are developed, this concern may limit their therapeutic application, such as in 6 
vaccination.  Quite recently, protein manipulation by binding anti-Aβ antibody to transferrin 7 
receptor, which is involved in receptor-mediated transcytosis, produced a monovalent “Brain 8 
Shuttle” module, leading to increased brain penetration.138)  Consequently, continuous 9 
investigations to develop oligomer-specific antibodies with high affinity will be required to 10 
move closer to the realization of a world without AD. 11 
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§“Conformation” in this context refers to tertiary structure of proteins including oligomers.   2 
§§“Conformer” in this context refers to isomers which are exclusively interconvertible by the 3 
single bond rotation without breaking the chemical bonds.  4 
 5 
Figure and Table legends 6 
Fig. 1.  Aβ-related and -unrelated Biomarkers Associated with Clinical Disease Stages during 7 
AD.  The Figure 1 in the reference6) was modified. 8 
CSF, cerebrospinal fluid; MCI, mild cognitive impairment. 9 
 10 
Fig. 2.  APP Processing with  α-, β-, γ-Secretases to Generate Aβ (Amyloidogenic Pathway) 11 
or Truncated Aβ (non-Amyloidogenic Pathway).  12 
sAPPα(β), secreted APPα(β); CTFα(β), C-terminal fragment α(β) of APP; AICD, APP 13 
intracellular domain. 14 
 15 
Fig. 3.  Schematic Aggregation Pathway of Aβ Based on the Dimer and Trimer as a Minimum 16 
Unit for Oligomerization.   17 
Aβ forms synaptotoxic oligomers to move into fibrillization (on-pathway), while to 18 
remain unchanged (off-pathway).   19 
 20 
Fig. 4.  Development of Antibody against Toxic Conformer of Aβ42.   21 
(A) A proposed mechanism of the formation of S-oxidized radical at Met35 and its 22 
stabilization within a C-terminal core to induce long-lasting oxidative stress by a partially 23 
cleaved carboxyl radical at Ala42 in Aβ42.  (B) Toxic conformation with a “toxic” turn at 24 
positions 22 and 23 and non-toxic conformation with a turn at positions 25 and 26 have been 25 
identified from solid-state NMR and systematic proline replacement studies.  26 
Immunohistochemical studies of anti-toxic turn antibody (11A1) using human AD brain 27 
sections.  Arrows indicate extracellular Aβ depositions (senile plaques), and arrowheads 28 
 32 
indicate the accumulation of intracellular Aβ within the cells, respectively.  Scale bar 1 
represent 100  µm. 2 
 3 
Table legend 4 
Table 1.  Synaptotoxic Aβ Oligomers of and Their Biological Activities Together with 5 
Antibody Development against These Oligomers. 6 
The three formers refer to the intermediates on the on-pathway into fibrillization, while 7 
the four latters refer to the assemblies on the off-pathway. 8 
 9 
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